Comparative Pharmacology
Head-to-head clinical analysis: MORPHINE SULFATE AUTOINJECTOR versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MORPHINE SULFATE AUTOINJECTOR versus QDOLO.
MORPHINE SULFATE (AUTOINJECTOR) vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate is a full opioid agonist that binds to mu-opioid receptors (MOR) in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain. It also activates delta and kappa receptors, contributing to analgesia and side effects.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Adult: 2–5 mg IV every 5–10 minutes as needed for pain; 10 mg IM every 4 hours as needed for pain. For autoinjector, typical dose is 5–10 mg IM or SC once.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged to 3-6 hours in elderly, neonates, or patients with hepatic/renal impairment. Clinical context: Half-life does not correlate directly with duration of analgesia; analgesic duration is 4-6 hours due to slow CNS equilibration.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal: 90% of morphine and its metabolites (morphine-3-glucuronide, morphine-6-glucuronide) are excreted in urine. About 7-10% is eliminated via bile and feces. Enterohepatic recirculation occurs.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist